1Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections [ J ]. N Engl J Med,2001,344(13) :984. 被引量：1
2Winston A, Boffito M. The management of HIV - 1 protease inhibitor pharmacokinetic interactions [ J ]. J Antimicrob Chemother,2005,56(1) : 1. 被引量：1
3Gallant JE. Protease inhibitor boosting in the treatment experienced patients [ J ]. AIDS Rev,2004,6 (4) :226. 被引量：1
4Zeldin RK, Petruschke RA. Pharmacological and therapeutic propertics of ritonavir - boosted protease inhibitor therapy in HIV - infected patients [ J ]. J Antimicrob Chemother,2004 ,53(1) :4. 被引量：1
5Plosker GL,Scott LJ. Saquinavir: a review of its use in boosted regiments for treating HIV infection [ J ]. Drugs,2003,63 (12) :1299. 被引量：1
6Walmsley S, Bernstein B, King M, et al. Lopinavir - ritonavir versus nalfinavir for the initial treatment of HIV infection [J]. N Engl J Meal,2002,346(26) :2039. 被引量：1
8Becker SL. The role of pharmacological enhancement in protease inhibitor - based highly active antiretroviral therapy [J]. Expert Opin lnvestig Drugs,2003,12(3) :401. 被引量：1
9Malta B, Michael K, Guido K, et al. Atazanavir enhances saquinavir hard - gel concentrations in a ritonavir-boosted once - daily regimen [ J ]. AIDS, 2004,18 ( 9 ) : 1291. 被引量：1
10Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV - 1 positive individuals receiving highly active retroviral therapy [ J ]. J Antimicrob Chemother,2005,56 ( 2 ) :380. 被引量：1
同被引文献91
1Gottesman MM, Pastan I. Biochemistry of multi- drug resistance mediated by the multidrug trans- porter[J]. Annu Rev Biochem, 1993, 62: 385- 427. 被引量：1
2Solon EG, Balani SK, Luo G, et al. Interaction of ritonavir on tissue distribution of a [(14) c] L-vali- namide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole- body autoradiography [ J ]. Drug Metab Dispos, 2002,30(11): 1164--1169. 被引量：1
3Drewe J, Gutmann H, Fricker G, et al. HIV prote- ase inhibitor ritonavir: a more potent inhibitor of P- glycoprotein than the cyclosporine analog SDZ PSC 833[J]. Biochem Pharmaeol,1999, 57(10) : 1147-- 1152. 被引量：1
4Shaik N, Pan G, Elmquist WF, et al. Interactions of pluronic block copolymers on P-gp efflux activi- ty: experience with HIV-1 protease inhibitors[J]. J Pharm Sci,2008,97(12) : 5421--5433. 被引量：1
5Kaddoumi A, Choi SU, Kinman L, et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid[J]. Drug Metab Dispos,2007, 35(9) :1459--1462. 被引量：1
6Storch CH, Theile D, Lindenmaier H,et al. Com- parison of the inhibitory activity of anti-HIV drugs on P-glycoprotein[J]. Biochem Pharmacol, 2007,73 (10) : 1573--1581. 被引量：1
7Haas DW, Wu HL, Bosch RJ,et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV- 1 infection., an adult AIDS Clinical Trials Group study[J]. J Acquir Immune Defic Syndr, 2003,34 (3) : 295--298. 被引量：1
8Lucia MB, Rutella S, Leone G, et al. HIV-prote- ase inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART[J]. J Acquir Immune Defic Syndr, 2001,27 (4) : 321 -- 230. 被引量：1
9Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions[J]. Life Sci, 2006,78 (18) : 2131--2145. 被引量：1
10Berginc K, Trdan T, Trontelj J,et al. HIV prote-ase inhibitors: garlic supplements and first-pass in- testinal metabolism impact on the therapeutic effica- cy[J]. Biopharm Drug Dispos, 2010 , 31 (8/9) : 495 --505. 被引量：1
